. Author manuscript; available in PMC: 2011 Dec 21.

Published in final edited form as: Eur J Cancer. 2010 Mar 19;46(9):1573–1579. doi: 10.1016/j.ejca.2010.02.047

Table 2. Adverse Events on Treatment (n = 32 evaluable patients).

Belinostat related toxicity CTCAE version 3.	Grade 1/2	Grade 3/4	Patients Total no. %
Fatigue	22	-	22 (69%)
Nausea	22	-	19 (59%)
Vomiting	11	-	11(34%)
Diarrhea	9	-	9(28%)
Pneumonitis	2	-	2(6%)
Sinus bradycardia	6	-	6(19%)
Sensory peripheral neuropathy	5	-	5(16%)
Headache	5	-	5(16%)
Hypersensitivity	2	1	3(9%)
Thrombosis	0	3	3(9%)
Leukopenia	2	-	2(6%)
Anemia	4	-	4(13%)
Elevated alkaline phosphatase	1	1	2(6%)